(CercleFinance.com) – AstraZeneca announced on Wednesday that Lynparza has been authorized by the European Union for the treatment of prostate cancer.
The green light from Brussels concerns the use of Lynparza in combination with abiraterone or prednisone in metastatic and castration-resistant prostate cancer in patients for whom chemotherapy is not indicated.
This approval follows the results of a phase III clinical study which had shown a 34% reduction in the risk of death in treated patients, which had prompted the European Medicines Agency to adopt a positive recommendation on the drug. last month.
Prostate cancer is now the most common in men in Europe, with 473,000 patients diagnosed in 2020 for 108,000 deaths.
AstraZeneca also announced this morning that Imfinzi has been approved by the European Union for the first-line treatment, alongside chemotherapy, of unresectable or metastatic bile duct cancer, a particularly aggressive form of cancer.
This treatment, which had also been the subject of a favorable opinion in November, showed a 20% reduction in the risk of death compared to chemotherapy alone during phase III trials.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
